Clinical Trials
7 trialsNCT06008054 2025-09-26
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT04152018 2025-05-28
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT04171141 2025-01-16
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Pfizer
Phase 1 Terminated
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT03222440 2019-12-04
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Completed
NCT03671265 2019-01-09
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown